Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 9/20 | 0.85 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CTSV | O60911 | 2/20 | 0.36 |
| ▸ | CTSL | P07711 | 2/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | PDE9A | O76083 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13097559 | 0.93 | CYP2D6 (0.87) | CYP2D6BRD4CTSVCTSLPDE9A | |
| SCHEMBL13097564 | 0.92 | CYP2D6 (0.85) | CYP2D6BRD4CTSVCTSLPDE9A | |
| SCHEMBL3101982 | 0.92 | CYP2D6 (1.00) | CYP2D6BRD4CTSVCTSLSLC2A1 | |
| SCHEMBL13097594 | 0.91 | CYP2D6 (0.84) | CYP2D6BRD4CTSVCTSLPDE9A | |
| SCHEMBL13349902 | 0.91 | CYP2D6 (0.84) | CYP2D6BRD4CTSVCTSLPDE9A | |
| SCHEMBL13097590 | 0.91 | CYP2D6 (0.86) | CYP2D6L3MBTL1ABCG2BRD4CTSV | |
| SCHEMBL13097890 | 0.91 | CYP2D6 (0.82) | CYP2D6L3MBTL1BRD4CTSVCTSL | |
| SCHEMBL13097622 | 0.90 | CYP2D6 (0.84) | CYP2D6BRD4CTSVCTSLPDE9A | |
| SCHEMBL13097569 | 0.89 | CYP2D6 (0.80) | CYP2D6BRD4PDE9ARAB9A | |
| SCHEMBL13097958 | 0.89 | CYP2D6 (0.80) | CYP2D6CTSVCTSLPDE9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2194044-A1 | QUINOLONE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256113-A1 | QUINOLONE DERIVATIVE | NQO1, NQO2, NADK | CYP2D6 230/4885L3MBTL1 2056/4885ABCG2 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.